【佳學(xué)基因檢測(cè)】在癌癥中靶向 p53

品牌基因檢測(cè)價(jià)格表還有嗎

比較做了備注《Curr Med Chem Anticancer Agents》在?2001 Aug;1(2):151-61發(fā)表了一篇題目為《在癌癥中靶向 p53》腫瘤靶向藥物治療基因檢測(cè)臨床研究文章。該研究由P Chène?等完成。促進(jìn)了腫瘤的正確治療與個(gè)性化用藥的發(fā)展，進(jìn)一步強(qiáng)調(diào)了基因信息檢測(cè)與分析的重要性。

腫瘤靶向藥物及正確治療臨床研究?jī)?nèi)容關(guān)鍵詞：

0

腫瘤靶向治療基因檢測(cè)臨床應(yīng)用結(jié)果

p53功能的喪失是癌癥中非常重要的事件。腫瘤中缺乏功能性 p53 有利于癌癥發(fā)展，并且有人認(rèn)為它也會(huì)影響化學(xué)療法和放射療法的功效。因此，p53 通路是學(xué)術(shù)界和工業(yè)界都在進(jìn)行深入研究的主題，以鑒定針對(duì) p53 改變的腫瘤的新化合物。目前正在研究不同的策略。它們可以分為兩組：生物策略和化學(xué)策略。生物學(xué)策略利用免疫系統(tǒng)來(lái)消除過度表達(dá) p53 突變體的腫瘤?；蛘?，他們使用在腫瘤或工程病毒中傳遞功能性 p53 基因的載體，選擇性地靶向 p53 缺陷細(xì)胞?；瘜W(xué)策略基于穩(wěn)定或激活 p53 突變蛋白、抑制 p53 和 hdm2 之間的相互作用或作用于 p53 結(jié)合伴侶蛋白的化合物的設(shè)計(jì)。在本次審查中，將分析這些不同方法的當(dāng)前進(jìn)展。

腫瘤發(fā)生與反復(fù)轉(zhuǎn)移國(guó)際數(shù)據(jù)庫(kù)描述：

The loss of p53 function is a very important event in cancer. The absence of a functional p53 in tumours favours cancer development, and it has been suggested that it also influences the efficacy of both chemotherapy and radiotherapy. The p53 pathway is therefore the subject of intense research, both in academia and in industry, to identify new compounds targeting tumours with an altered p53. Different strategies are currently under investigation. They can be divided into two groups: biological and chemical strategies. The biological strategies utilise the immune system to eliminate the tumours overexpressing p53 mutants. Alternatively they use vectors delivering a functional p53 gene in tumours or engineered viruses, which selectively target p53-defective cells. The chemical strategies are based on the design of compounds that stabilise or activate the p53 mutant proteins, inhibit the interaction between p53 and hdm2, or act on the p53-binding chaperone proteins. In this review, the current progress in these different approaches will be analysed.